DBV Technologies S.A. DBVT

DBVT Company Overview

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies using its proprietary epicutaneous immunotherapy (EPIT) platform. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on immunology and allergy-related diseases. DBV Technologies’ lead product candidate is Viaskin Peanut, a skin-applied patch designed to desensitize patients with peanut allergy, particularly children.

Founded in 2002 in France, DBV Technologies has evolved from a platform-focused biotech into a late-stage clinical company centered on food allergy immunotherapy. Its strategy is built around addressing significant unmet medical needs in allergy treatment through non-invasive, patient-friendly delivery methods. The company’s differentiation lies in its EPIT technology, which delivers allergens through intact skin without systemic exposure, aiming to improve safety compared with traditional immunotherapy approaches.